通心络胶囊对冠心病患者PCI术后血清亲环素A和基质金属蛋白酶9的影响

发布时间：2018-05-01 05:01

本文选题：冠心病 + 经皮冠状动脉介入治疗　；参考：《中国药房》2017年24期

【摘要】：目的:探讨通心络胶囊对冠心病患者经皮冠状动脉介入治疗(PCI)术后血清亲环素A(CyPA)和基质金属蛋白酶9(MMP-9)的影响。方法:拟行PCI术的115例冠心病患者随机分为对照组(59例)和观察组(56例)。对照组患者给予常规治疗;观察组患者在对照组治疗的基础上于术后第1天开始口服通心络胶囊0.78 g,每日3次,连用6个月。观察两组患者手术前后的CyPA、MMP-9水平及不良反应发生情况。结果:术前,两组患者血清CyPA、MMP-9水平比较,差异均无统计学意义(P0.05)。两组患者术后1 d、1个月及对照组患者术后6个月CyPA水平均显著高于同组术前,但观察组术后1、6个月显著低于对照组,且随时间延长逐渐降低,差异均有统计学意义(P0.05);术后1 d两组间及观察组术后6个月CyPA水平与术前比较,差异均无统计学意义(P0.05)。两组患者术后1 d、1个月MMP-9水平均显著高于同组术前,但观察组显著低于对照组,且随时间延长逐渐降低,差异均有统计学意义(P0.05);两组患者术后6个月MMP-9水平与术前比较,差异均无统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:在常规治疗的基础上,通心络胶囊可显著降低冠心病患者PCI术后的CyPA、MMP-9水平,且未增加不良反应的发生。
[Abstract]:Objective: to investigate the effect of Tongxinluo capsule (TXL) on serum cyclophile Acycline (Acyclin) and matrix metalloproteinase 9 (MMP-9) after percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD). Methods: one hundred and fifteen patients with coronary heart disease were randomly divided into control group (n = 59) and observation group (n = 56). The patients in the control group were given routine treatment, and the patients in the observation group were given Tongxinluo capsule 0.78 g on the first day after operation, 3 times a day for 6 months. The level of MMP-9 and the incidence of adverse reactions were observed before and after operation. Results: there was no significant difference between the two groups in the serum levels of CyPA-MMP-9 before operation (P 0.05). The level of CyPA in the two groups was significantly higher than that in the control group at 1 day, 1 month and 6 months after operation, but the level of CyPA in the observation group was significantly lower than that in the control group at 1 and 6 months after operation, and decreased gradually with the prolongation of time. There was no significant difference in CyPA level between the two groups and 6 months after operation, and there was no significant difference between the two groups on the 1st day after operation and 6 months after operation (P 0.05). The level of MMP-9 in the two groups was significantly higher than that in the same group at 1 day and 1 month after operation, but the level of MMP-9 in the observation group was significantly lower than that in the control group, and gradually decreased with the prolongation of time, the difference being statistically significant (P 0.05), the level of MMP-9 in the two groups at 6 months after operation was compared with that before operation. The difference was not statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: Tongxinluo capsule can significantly reduce the level of CyPA-MMP-9 in patients with coronary heart disease after PCI, and does not increase the incidence of adverse reactions on the basis of routine treatment.
【作者单位】：宣城市人民医院;
【分类号】：R541.4

【相似文献】